USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Israeli generics giant Teva Pharmaceutical Industries felt the force of a Friday battering in the stock market after reducing its revenue forecast for 2017 by more than $1 billion. 6 January 2017
The board of directors of US biotech Biogen has approved the spin-off of its hemophilia business, which will be known as Bioverativ Inc. 21 December 2016
USA-based RNAi therapeutics company Alnylam Pharmaceuticals jumped by nearly 3% to $44.39 in Friday’s trading after presenting its 2017 pipeline goals. 19 December 2016
Shares in US pharma major Eli Lilly were up by 4.5%, at $70.71, by lunchtime on Thursday following the company’s announcement of its 2017 financial guidance and outlook for the next decade. 15 December 2016
Projected returns on investment in research and development (R&D) for the top 12 pharma companies have fallen to their lowest level in six years, reveals a new report from Deloitte’s Centre for Health Solutions. 14 December 2016
The announcement that 700 US jobs are to be cut by one of pharma’s big names comes in the week that two other leading companies are to slash their workforce. 9 December 2016
UK biotech Kymab has taken a major step forward in advancing its proprietary pipeline of first-in-class therapeutic human monoclonal antibodies. 24 November 2016
Spanish drugmaker Grifols raised 1 billion euros ($1.06 billion) in revenue in the third quarter of 2016, a 3% increase compared with the same period the previous year. 18 November 2016
The share price of Israeli generics giant Teva dropped by more than 8% on Tuesday, when the company announced its third quarter results. 16 November 2016
Ireland-incorporated Shire closed 3.7% higher at £5,087 on Thursday after it showcased a strong rare diseases pipeline and commercial portfolio in an investor day. 10 November 2016
Jordan-based Hikma Pharmaceuticals (was trading 4% lower as Thursday’s trading neared its end while markets digested its third-quarter trading update. 10 November 2016
The struggles and successes of UK biotechs in raising capital show the particular challenges of accessing funds on different sides of the Atlantic, as Chris Pettigrew of Novasecta explores in our expert view piece. 8 November 2016
Spain’s leading drugmaker Almirall has reported revenues for 2016’s first three quarters which are 6.7% higher than in the same period last year. 7 November 2016
Ireland-incorporated Allergan might have seen its third quarter revenue rise by 4.4% compared to the same period last year, but the $3.62 billion total was shy of analyst estimates of $3.68 billion. 3 November 2016
Shares in cancer drug developer Verastem and pharma company Infinity Pharmaceuticals both dropped significantly on Wednesday after the US companies announced a $28 million licensing deal on an oncology candidate. 3 November 2016
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news